<p>Nkgen Biotech Inc. has announced that Dr. Yong Man Kim will transition from his role as an employee to serve as Chief Scientific Officer in a consulting capacity. This change follows Dr. Kim’s recent appointment as President of NKMax. He will continue to provide scientific leadership and support for Nkgen Biotech’s research and development efforts. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nkgen Biotech Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-093062), on September 29, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here</p>

NKGN

<p>Nkgen Biotech Inc. has appointed Dr. Yong Man Kim as Consulting Chief Scientific Officer after his transition to President of NKMax. Dr. Kim will continue to lead and support Nkgen Biotech’s research and development efforts in this new consulting role.</p>

Nkgen Biotech Appoints Dr. Yong Man Kim as Consulting Chief Scientific Officer Following Transition to NKMax President